Hepatitis Viruses A Through E

Understanding the five primary hepatotropic viruses—A, B, C, D, and E—is fundamental for any medical career. These viruses are a leading global cause of liver inflammation, yet they differ dramatically in their transmission, potential for chronic disease, and clinical management. For the MCAT and medical school, you must move beyond memorizing a list to grasping the comparative pathophysiology that explains why a needle-stick exposure warrants concern for one virus but not another, and why a pregnant patient with jaundice requires a different diagnostic approach.

Viral Foundations: Structure, Genome, and Transmission Pathways

The hepatitis viruses are classified by their genetic material and mode of transmission, which are the primary determinants of their behavior. Hepatitis A virus (HAV) is a single-stranded, positive-sense RNA virus transmitted via the fecal-oral route. This typically occurs through contaminated food or water, or close personal contact. In contrast, Hepatitis B virus (HBV) is a partially double-stranded DNA virus that replicates via an RNA intermediate, a unique process involving reverse transcriptase. HBV is transmitted via exposure to infectious blood, semen, and other body fluids, making it a risk for needle-sharing, sexual contact, and perinatal transmission.

Hepatitis C virus (HCV) is a single-stranded, positive-sense RNA virus with a high mutation rate. Its primary route is bloodborne transmission, historically through transfusions and now most commonly via injection drug use. Hepatitis D virus (HDV), or delta virus, is a defective RNA virus that requires the presence of HBV to provide its viral envelope for replication. Therefore, HDV infection only occurs as a coinfection with acute HBV or as a superinfection in a person already chronically infected with HBV. Finally, Hepatitis E virus (HEV) is an RNA virus, similar to HAV in its fecal-oral transmission, often linked to contaminated water in developing regions.

Clinical Course: From Acute Hepatitis to Chronic Disease

The initial phase of infection for all hepatitis viruses can cause acute viral hepatitis, characterized by nonspecific symptoms like fatigue, nausea, abdominal pain, and jaundice. However, the long-term outcomes diverge sharply based on the virus's ability to establish chronic infection.

HAV and HEV typically cause acute self-limited hepatitis, meaning the infection resolves completely without progressing to a chronic state. The immune system clears the virus, often conferring lifelong immunity. The critical exception is Hepatitis E in pregnant women, particularly during the third trimester, where it can cause fulminant hepatic failure with a mortality rate as high as 20-30%.

The major concern with HBV and HCV is their propensity for chronic infection, defined as persistence of the virus for more than six months. The risk is age-dependent. For HBV, approximately 90% of infected infants will develop chronic infection, compared to only 5% of immunocompetent adults. Chronic HBV can lead to cirrhosis (scarring of the liver) and hepatocellular carcinoma (HCC), a primary liver cancer. HCV becomes chronic in about 75-85% of infected individuals. Over decades, chronic HCV is a major cause of cirrhosis and is also strongly associated with the development of HCC.

HDV infection dramatically worsens the prognosis of HBV. A simultaneous coinfection with HBV and HDV often leads to a more severe acute hepatitis but a similar low rate of chronicity as HBV alone. However, HDV superinfection in a chronic HBV carrier frequently accelerates the course of liver disease, leading to cirrhosis and liver failure much more rapidly.

Diagnostic Serology: The Key to Identification

For the MCAT and clinical practice, interpreting serological markers is essential. Each virus has a distinct antibody and antigen profile.

• Hepatitis A: Diagnosis is confirmed by detecting IgM anti-HAV in acute infection. IgG anti-HAV indicates past infection or vaccination and confers immunity.
• Hepatitis B: This requires understanding several markers:
• HBsAg (Surface Antigen): Presence indicates current infection (acute or chronic). Its disappearance signals clearance.
• Anti-HBs: Presence indicates immunity, either from recovery or vaccination.
• HBcAg (Core Antigen): Not detectable in serum, but antibodies to it are.
• IgM anti-HBc: Marker of recent acute infection (within 6 months).
• Total anti-HBc (IgG + IgM): Positive in anyone ever infected with HBV.
• HBeAg and Anti-HBe: Markers of viral replication and infectivity. HBeAg positivity indicates high viral load.
• Hepatitis C: Screening is done with an antibody test (anti-HCV). A positive antibody test is followed by an HCV RNA PCR test to confirm active viremia and chronic infection.
• Hepatitis D: Diagnosed by detecting anti-HDV antibodies or HDV RNA. The presence of HBsAg is a prerequisite.
• Hepatitis E: Diagnosed by detecting IgM anti-HEV or HEV RNA in serum or stool.

Prevention, Management, and MCAT Priorities

Prevention strategies are dictated by transmission routes. For fecal-oral viruses (HAV, HEV), prevention focuses on sanitation, safe food/water handling, and vaccination (available for HAV). For blood/fluid-borne viruses (HBV, HCV, HDV), prevention involves blood supply screening, safe injection practices, and use of barrier protection. A highly effective vaccine exists for HBV, which also prevents HDV infection. There is no vaccine for HCV or HEV in the US (one exists in China).

Management differs fundamentally:

• HAV/HEV: Supportive care only, as infection is self-limiting.
• HBV: Chronic infection may be managed with pegylated interferon or nucleos(t)ide analogue antivirals (e.g., entecavir, tenofovir) to suppress viral replication.
• HCV: Chronic infection is now curable in over 95% of cases with direct-acting antiviral (DAA) regimens, such as sofosbuvir/ledipasvir.
• HDV: Treatment is challenging; pegylated interferon-alpha is the mainstay, but new therapies are emerging.

For the MCAT, focus on the high-yield comparisons: RNA vs. DNA genomes, which viruses have vaccines, which become chronic, and the unique aspects of HBV serology and HDV's defective nature.

Common Pitfalls

1. Confusing Transmission Routes: A common mistake is grouping all hepatitis viruses as "blood-borne." Remember, HAV and HEV are primarily spread fecal-orally. Associating a patient's history (e.g., restaurant outbreak vs. needle stick) with the correct virus is critical.
2. Misunderstanding Chronicity: Not all viruses cause chronic disease. HAV and HEV (except in pregnancy) do not. The risk of chronicity for HBV is inversely related to age at infection, while HCV is highly chronic regardless.
3. Overlooking the HBV/HDV Relationship: It's easy to forget that HDV cannot cause infection on its own. Always check for HBV (HBsAg) when considering HDV. Superinfection is a classic cause of sudden clinical deterioration in a stable chronic HBV patient.
4. Incorrect Serology Interpretation: Particularly with HBV, confusing HBsAg with Anti-HBs is a major error. HBsAg = current infection. Anti-HBs = immunity. A patient who is vaccinated will have Anti-HBs but will be negative for all other markers.

Summary

• Hepatitis A is an RNA virus spread fecal-orally, causing acute self-limited hepatitis; prevention includes vaccine and sanitation.
• Hepatitis B is a DNA virus transmitted via blood/body fluids; it carries a significant risk of chronic infection leading to cirrhosis and hepatocellular carcinoma, but is preventable by a highly effective vaccine.
• Hepatitis C is an RNA bloodborne virus that becomes chronic in most patients, representing a major cause of liver disease worldwide, though now curable with direct-acting antivirals.
• Hepatitis D is a defective RNA virus that requires concurrent HBV infection to replicate and significantly worsens liver disease.
• Hepatitis E is an RNA fecal-oral virus that is typically acute but can cause severe or fulminant hepatitis in pregnant women.